Investigation of image-based lesion and kidney dosimetry protocols for 177Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition

Sandra Resch; Sarah Takayama Fouladgar; Mathias Zacherl; Gabriel T Sheikh; Grigory Liubchenko; Mikhail Rumiantcev; Lena M Unterrainer; Vera Wenter; Peter Bartenstein; Sibylle I Ziegler; Harun Ilhan; Leonie Beyer; Guido Böning; Astrid Delker

doi:10.1186/s40658-023-00529-8

Investigation of image-based lesion and kidney dosimetry protocols for ¹⁷⁷Lu-PSMA-I&T therapy with and without a late SPECT/CT acquisition

EJNMMI Phys. 2023 Feb 9;10(1):11. doi: 10.1186/s40658-023-00529-8.

Affiliations

¹ Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. sandra.resch@med.uni-muenchen.de.
² Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.

Abstract

Background: ¹⁷⁷Lu-PSMA therapy has been successfully used to prolong the survival of patients with metastatic castration-resistant prostate cancer. Patient-specific dosimetry based on serial quantitative SPECT/CT imaging can support the understanding of dose-effect relationships. However, multiple SPECT/CT measurements can be challenging for patients, which motivates the investigation of efficient sampling schedules and their impact on dosimetry. In this study, different time samplings with respect to the number and timing of SPECT/CT acquisitions with and without a late measurement were investigated.

Materials and methods: In total, 43 lesions and 10 kidneys of 5 patients receiving ¹⁷⁷Lu-PSMA-I&T therapy were investigated. Whole-body SPECT/CT measurements were performed at 1, 2, 3 and 7 days post-injection. For both lesions (isocontour-based segmentation) and kidneys (CT-based segmentation), a reference model was employed including all four time points. To identify the best-matching fit function out of a pre-defined set of models, visual inspection, coefficients of variation and sum of squared errors were considered as goodness-of-fit criteria. Biologically effective doses (BEDs) calculated with different time samplings (days 1, 2, 3/1, 2, 7/1, 3, 7/2, 3, 7 and 1, 2/1, 3/1, 7) were compared to the reference.

Results: The best-fit function was found to be a mono-exponential model for lesions and a bi-exponential model with a population-based parameter and two free parameters for kidneys. The BEDs calculated with the time sampling 1, 3, 7 days showed the lowest deviations from the reference for lesions with 4 ± 5%. Without day 7, still 86% of all lesions showed deviations from the reference < 10%. The outlier deviations showed a positive correlation with the effective half-life of the respective lesions. For kidneys, including days 1, 2, 3 achieved the best results with 0 ± 1%. Generally, deviations for kidneys were found to be small for all time samplings (max. 13%).

Conclusions: For combined optimization of the SPECT/CT time sampling for kidney and lesion dosimetry during ¹⁷⁷Lu-PSMA-I&T therapy, the sampling with days 1, 3, 7 showed the smallest deviation from the reference. Without a late acquisition, using the schedule with days 1, 2, 3 is likewise feasible.

Keywords: 177Lu; Dosimetry; PSMA; Prostate cancer; SPECT.